TABLE 1.

Demographic, Clinical, and Virological Features of the Participants

Variable	Total n = 1,036	WT n = 478 (46.3%)	PC G1896A only n = 190 (18.4%)	BCP only n = 250 (24.2%)	BCP and PC G1896A n = 114 (11.0%)
Sex	n = 1,036	n = 478	n = 190	n = 250	n = 114
Male	507 (48.9%)	208 (41.1%)	104 (20.6%)	130 (25.7%)	64 (12.6%)
Female	529 (51.1%)	270 (51.3%)	86 (16.3%)	120 (22.8%)	50 (9.5%)
Race	n = 1,031	n = 475	n = 188	n = 250	n = 114
White	100 (9.7%)	49 (49.0%)	13 (13.0%)	23 (23.0%)	15 (15.0%)
Black	137 (13.3%)	64 (47.1%)	24 (17.6%)	34 (25.0%)	14 (10.3%)
Asian	765 (74.2%)	353 (46.3%)	143 (18.8%)	185 (24.3%)	81 (10.6%)
Other/mixed	29 (2.8%)	9 (31.0%)	8 (27.6%)	8 (27.6%)	4 (13.8%)
Age (years)	n = 1,036	n = 478	n = 190	n = 250	n = 114
0–18	228 (22.0%)	171 (75.0%)	21 (9.2%)	31 (13.6%)	5 (2.2%)
>18–40	377 (36.4%)	185 (49.1%)	66 (17.5%)	95 (25.2%)	31 (8.2%)
>40	431 (41.6%)	122 (28.6%)	103 (24.1%)	124 (29.0%)	78 (18.3%)
HBeAg status	n = 1,033	n = 476	n = 190	n = 249	n = 114
Negative	572 (55.4%)	164 (28.9%)	165 (29.0%)	134 (23.6%)	105 (18.5%)
Positive	461 (44.6%)	312 (67.7%)	25 (5.4%)	115 (24.9%)	9 (2.0%)
Genotype	n = 1,028	n = 475	n = 189	n = 247	n = 113
A	185 (18.0%)	106 (57.6%)	14 (7.6%)	54 (29.3%)	10 (5.4%)
B	374 (36.4%)	180 (48.3%)	112 (30.0%)	45 (12.1%)	36 (9.7%)
C	339 (33.0%)	142 (41.9%)	28 (8.3%)	127 (37.5%)	42 (12.4%)
D	87 (8.5%)	35 (41.2%)	17 (20.0%)	16 (18.8%)	17 (20.0%)
E	36 (3.5%)	10 (27.8%)	16 (44.4%)	3 (8.3%)	7 (19.4%)
Other (F, G, and multiple)	7 (0.7%)	2 (28.6%)	2 (28.6%)	2 (28.6%)	1 (14.3%)
HBV DNA (log10 IU/mL)	n = 1,036	n = 478	n = 190	n = 250	n = 114
<4	386 (37.3%)	134 (35.0%)	108 (28.2%)	79 (20.6%)	62 (16.2%)
4-<6	207 (20.0%)	42 (20.4%)	55 (26.7%)	71 (34.5%)	38 (18.4%)
6-<8	146 (14.1%)	67 (45.9%)	14 (9.6%)	54 (37.0%)	11 (7.5%)
>=8	297 (28.7%)	235 (79.1%)	13 (4.4%)	46 (15.5%)	3 (1.0%)

Note: Bolded rows indicate the number of study subjects with available data.